Regorafenib therapy as a third-line treatment for metastatic colorectal cancer: A single center long term experience

This study examined the effects of regorafenib (Reg) on progression-free survival (PFS), overall survival (OS), and adverse events (AEs) in metastatic colorectal cancer (mCRC) patients who underwent targeted treatment and chemotherapy. Reg was administered as a third-line treatment to 84 patients wh...

Full description

Saved in:

Bibliographic Details
Published in:	Medicine (Baltimore) Vol. 102; no. 50; p. e36435
Main Authors:	Ozkan, Merve, Oflazoglu, Utku, Yildiz, Yaşar, Güc, Zeynep G, Salman, Tarik, Ünal, Sinan, Kücükzeybek, Yüksel, Alacacioglu, Ahmet
Format:	Journal Article
Language:	English
Published:	United States Lippincott Williams & Wilkins 15-12-2023
Subjects:	Antineoplastic Combined Chemotherapy Protocols - therapeutic use Colonic Neoplasms - drug therapy Colorectal Neoplasms - pathology Humans Observational Study Proto-Oncogene Proteins B-raf - genetics
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	This study examined the effects of regorafenib (Reg) on progression-free survival (PFS), overall survival (OS), and adverse events (AEs) in metastatic colorectal cancer (mCRC) patients who underwent targeted treatment and chemotherapy. Reg was administered as a third-line treatment to 84 patients who had undergone 2 rounds of chemotherapy and targeted therapy and subsequently experienced progression. Treatment was initiated with a daily dose of 80 or 120 mg, based on the patient's ability to tolerate the medication, which was increased to 160 mg/day. The median PFS with Reg was 4 ± 0.2 months, while the median OS was 9 ± 1.2 months. When compared to patients who started Reg treatment at 80 mg, patients starting at 160 mg had longer median PFS and OS (PFS:6 ± 2.1 months vs 4 ± 0.2 months; P = .05; OS:13 ± 0.7 months vs 6 ± 1.3 months; P = .069). Patients with right-sided colon cancer who received Reg as third-line therapy had a significantly longer mPFS than those with left-sided colon cancer (8 months ± 4 vs 4 months ± 0.3, P = .039). Patients with KRAS mutations had a prolonged mPFS than those with panRAS-wild type (6 ± 1.6 months vs 4 ± 0.3 months, P = .06). The mPFS contribution in the BRAF mutant subgroup with poor prognosis is promising, as it is similar to that of patients without BRAF mutations (4 months ± 0.8 × 4 months ± 0.5, P = .74). The most common AEs reported were elevated liver enzyme levels and dermatological toxicities.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	0025-7974 1536-5964
DOI:	10.1097/MD.0000000000036435